

44. The conjugate of claim 40, wherein said substantially non-antigenic polymer is polyethylene glycol.

45. The alpha-interferon-conjugate of claim 40, wherein said conjugate has at least about 10% of the activity of unmodified alpha-interferon measured under the same conditions when said conjugate is administered subcutaneously in a mammal.

46. The alpha-interferon-conjugate of claim 42, wherein said conjugate has at least about 10% of the activity of unmodified alpha-interferon measured under the same conditions when said conjugate is administered subcutaneously in a mammal.

47. The alpha-interferon-conjugate of claim 40, wherein said conjugate has at least about 10% of the activity of unmodified alpha-interferon measured under the same conditions, and a $T_{1/2}$ of about 5 hours alpha phase when said conjugate is administered subcutaneously in a mammal.

48. The alpha-interferon-conjugate of claim 42, wherein said conjugate has at least about 10% of the activity of unmodified alpha-interferon measured under the same conditions, and a $T_{1/2}$ of about 5 hours alpha phase when said conjugate is administered subcutaneously in a mammal --

REMARKS

Applicants submit herewith new claims 40 through 48 for consideration. It is noted that these claims substantially correspond to composition claims presented in the parent application, U.S. Serial No. 08/337,567, filed November 10, 1994, and canceled without prejudice therein. Support for new can be found throughout the specification and Example 10. No new matter has been entered.

Applicants have also enclosed a check in the amount of \$ 362.00. If it is determined that an overpayment has been made or that additional fees are required, the Assistant Commissioner is hereby authorized to credit or debit such sum with Deposit Account No. 50-0217.